Genmab — Maj 2018
-
Spændende at se hvad der sker i luk?
-
Man kan godt frygte lidt at A/B presser den yderligere ned.
-
Jeg tror såmænd ikke dem som sælger i dag har set på regnskabet. De kan bare have samlet sammen hen mod regnskabet.
-
De har ihvertfald finger dybt presset ned på salgsknappen...
-
pt. nettosalg 97.000 stk
-
Jeg ser på det jkj. Tidsplanen er dog meget stra
m i dag. -
Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma. Lille studie, men 100% ORR. https://link.springer.com/article/10.1007/s12185-017-2390-2
-
the addition of daratumumab to Rd led to prolonged PFS with increased and deeper responses compared with Rd alone in both East Asian patients and Japanese patients from POLLUX, consistent with findings in the international POLLUX population. Given the recent approval of daratumumab in combination with lenalidomide and dexamethasone as a new treatment option in Japan13, these findings suggest that this regimen is a new standard of care for Japanese patients with RRMM
-
Tak gentogen. Jans optimisme med Japan er velbegrundet.
-
Q&A starter om 5 minutter.
-
Tusinde tak for mange gode og skarpe spørgsmål til alle.
-
@jkj, lige mine tanker
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind